Trials
8 active
15 in total · 9 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Relapsing Forms of Multiple Sclerosis
- Main trialPhase 3
- “In this study, researchers will learn more about the study drugs diroximel fumarate (DRF) and dimethyl fumarate (DMF) in children with MS who may be experiencing relapses. Participants will be divided into 2 groups based on their weight: * Group A will include children who weigh 40 kilograms (kg) or less. They will receive DRF in both Part 1 and Part 2 of the study. * Group B will include children who weigh more than 40 kg. They will be randomly assigned to receive DRF, DMF, or fingolimod. Fingolimod is a drug already used to treat MS in adults. In Part 2, they will receive DRF. This is a…”In the company’s words, NCT07483632 on ClinicalTrials.gov
- Other names
- Dimethyl Fumarate · Tecfidera · DMF
Other drugs for Relapsing Forms of Multiple Sclerosis
- IMU-838Immunic AG · Phase 3
- CT-P53Celltrion · Phase 3
- ABP 692Amgen · Phase 3
- FrexalimabSanofi · Phase 3
- Peginterferon beta-1aBiogen · Phase 3
- PrivosegtorOculis · Phase 3
Coming up1
- 28 Jul 2034Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials15
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 28 Jul 2034 | A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) | |
| Phase 4Completed | 12 Jun 2017 | Tecfidera and the Gut Microbiota | |
| Phase 4Completed | 27 Mar 2025 | A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China | |
| Phase 3Terminated | 21 Jul 2022 | Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants | |
| Phase 3Completed | 8 Jul 2025 | Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) | |
| Phase 2Completed | 31 Mar 2006 | Efficacy and Safety of BG00012 in MS | |
| Phase 1Completed | 18 Mar 2011 | Alternate Dosing Regimens of BG00012 in Healthy Volunteers | |
| Phase 2Authorised | not given | A double-blind, randomized, placebo-controlled trial to test the efficacy, safety and tolerability of Dimethyl Fumarate in Friedreich Ataxia (DMF-FA-201). | |
| Phase 2/3Authorised | not given | Effect of dimethyl fumarate administered to patients with adrenomyeloneuropathy: a multicenter, placebo controlled, phase IIb/III trial | |
| Phase 2Authorised | not given | LADIGAGA - Long–term Analysis of DImethyl fumarate, to slow the Growth of Areas of Geographic Atrophy | |
| Phase 3Authorised | not given | DESIRE MS: A prospective randomized non-inferiority trial comparing anti-CD20 maintenance versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis | |
| Phase 3Authorised | not given | DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMIZED, CONTROLLED, OPEN-LABEL CLINICAL TRIAL - TWINS | |
| Phase 3Authorised | not given | STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years | |
| Phase 2Authorised | not given | Randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of dimethyl fumarate in brain atrophy reduction, synaptic functional connectivity, cognitive functions, quality of life, and activity of daily living improvement among patients with mild cognitive impairment and dementia due to Alzheimer’s disease | |
| Phase 2Not authorised | not given | Phase 2, randomized, blinded, non-treatment-controlled study assessing the efficacy and safety of dimethyl fumarate in patients with NBIA, a neurodegeneration associated with brain iron accumulation. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026